No Known Mutations

IRB#9902  
Nivolumab or Nivolumab + Ipilimumab in Advanced or Metastatic Solid Tumors

IRB#10177  
MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors

IRB#11638  
ACP-196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma

IRB#11804  
Lenvatinib + Keytruda in Subjects with Solid Tumors

IRB#12008  
PDR001 in Patients with Advanced Malignancies

IRB# 20363  
PDR001 rollover study

IRB# 16198  
TTI-621 in subjects with melanoma

No Known Mutations

IRB# 16732  
BMS-986175, Nivolumab and/or Ipilimumab in Subjects with Advanced Solid Tumors

IRB# 16804  
DCC-3014 in subjects with advanced malignancies

IRB# 17521  
Study of SNDX-6352 and SNDX-6352 with Durvalumab in Patients with Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

IRB# 18111  
PDR001 + LAG525 in subjects with solid tumors

IRB# 18118  
Study of BA3011 in patients with advanced solid tumors

IRB# 18303  
Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

IRB# 18498  
Study of BA3021 in patients with advanced solid tumors

IRB# 19277  
Study coming soon

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

12/2/2019

http://www.ohsu.edu/research/rda/so/knight.php
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB# 19388</td>
<td>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors</td>
<td></td>
</tr>
<tr>
<td>IRB# 19390</td>
<td>A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Entrectinib</td>
<td></td>
</tr>
<tr>
<td>IRB# 20399</td>
<td>Study coming soon</td>
<td></td>
</tr>
<tr>
<td>IRB# 16702</td>
<td>A Phase I/IIa Trial With BMS-986158 as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors</td>
<td></td>
</tr>
<tr>
<td>IRB# 18788</td>
<td>Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)</td>
<td></td>
</tr>
<tr>
<td>IRB# 15206</td>
<td>Entrectinib in Patients with Advanced or Metastatic Solid Tumors</td>
<td></td>
</tr>
<tr>
<td>IRB# 17674</td>
<td>Loxo-105 in fusion-NTRK (previously treated) solid tumors</td>
<td></td>
</tr>
<tr>
<td>IRB# 16676</td>
<td>BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors</td>
<td></td>
</tr>
<tr>
<td>IRB# 18164</td>
<td>A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity</td>
<td></td>
</tr>
</tbody>
</table>

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

12/2/2019

http://www.ohsu.edu/research/rda/so/knight.php